secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALUMIS INC. (ALMS)
CIK:        0001847367
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001104659-24-117704
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alumis reports Q3 net loss of $93.1M; cash of $361.9M funds operations into 2026
--------------------------------------------------------------------------------

- Net loss of $93.1M in Q3 2024 vs $43.4M in Q3 2023; R&D expenses rose to $87.8M from $37.8M, including $23M milestone payment for FronThera acquisition.
- Cash and marketable securities of $361.9M as of Sept 30, 2024, expected to fund operations into 2026.
- ESK-001 Phase 3 ONWARD psoriasis trials on track; topline results expected H1 2026. Phase 2b SLE data expected 2026.
- A-005 Phase 1 data expected by year-end 2024; Phase 2 MS trial initiation planned 2025.
- Presented EADV data: ESK-001 40mg BID achieved 93% PASI 75 at 28 weeks (observed); supports ongoing Phase 3 dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847367/000110465924117704/0001104659-24-117704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847367/000110465924117704/tm2428191d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-117704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer